Strategic Signals Weekly

Genprex, Inc. announced a collaboration with Roche Diagnostics to validate TROP2 and PTEN as biomarkers for patient selection in non-small cell lung cancer (NSCLC) clinical trials. This strategic partnership aims to leverage Roche's assay development expertise and a previously FDA Breakthrough Device Designated TROP2 antibody to refine patient identification, potentially shortening recruitment times and enabling more personalized treatment. Genprex anticipates completing validation studies by late 2026 for subsequent integration into its NSCLC clinical program.

Lantheus Holdings, Inc. has entered into a definitive merger agreement to be acquired by Curium US Holdings LLC. Shareholders will receive $102.50 per share in cash and one Contingent Value Right (CVR) for up to an additional $12.00 per share based on commercial milestones. This transaction will result in Lantheus becoming a wholly owned subsidiary of Curium.

Partner: Curium US Holdings LLC

iSpecimen Inc. completed a "reasonable best efforts" public offering, issuing 996,231 shares of common stock and pre-funded warrants to purchase up to 2,849,923 shares of common stock. The aggregate purchase price for the offering was $5,000,000. The company intends to use the proceeds for repayment of outstanding liabilities, potential acquisitions, marketing and advertising services, and working capital.

Scholar Rock Holding Corporation filed a prospectus supplement to offer up to an additional $200 million in common stock through an at-the-market (ATM) offering program with Jefferies LLC. This new offering supersedes a prior one, and the company has already raised approximately $257.7 million in net proceeds from the ATM program to date.

Ensysce Biosciences entered into a Securities Purchase Agreement for a private placement, agreeing to issue and sell 120,260 shares of Series C Preferred Stock for approximately $43 million. The financing will occur in two tranches, with an initial closing expected on August 7, 2026, and a second tranche contingent on a clinical trial milestone.

Tarsus Pharmaceuticals, Inc. entered into a Securities Purchase Agreement for a private placement with a syndicate of existing and new healthcare investors. The company expects to receive approximately $125.0 million in gross proceeds from the sale of common stock and pre-funded warrants. The net proceeds are intended to fund clinical development, commercial activities, and general corporate purposes.

Tarsus Pharmaceuticals, Inc. announced its acquisition of Alkeus Pharmaceuticals, Inc. for an upfront consideration of $270 million in cash and $180 million in stock, totaling $450 million. The deal also includes up to $350 million in regulatory and sales milestones, plus tiered revenue sharing on gildeuretinol net sales. The acquisition is expected to close in 2026, subject to customary conditions.